Observational data shows CKM therapy reduces UACR in patients with Type 1 diabetes and CKD, suggesting efficacy and safety.
CKM therapy was frequently used in patients with Type 1 diabetes and CKD, associated with UACR reduction and safe. These clinically relevant data warrant confirmation in randomised clinical trials.
No takes yet. Share an insight, caveat, or question.
Caramori et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: